Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy
This study intends to describe the real-life effectiveness and safety of nivolumab in advanced NSCLC patients in Germany, as well as the patient profile, pattern of use and the quality of life.
Non-Small Cell Lung Cancer
Overall Survival (OS), Approximately 5 years
Progression-Free Survival (PFS), Approximately 5 years|Overall Response Rate (ORR), Approximately 5 years|Best Overall Response Rate (BORR), Approximately 5 years|Best Overall Response (BOR), Approximately 5 years|Duration of Response (DOR), Approximately 5 years|Distribution of socio-demographic characteristics in adult patients diagnosed with advanced NSCLC, At baseline and for up to 5 years|Distribution of clinical characteristics in adult patients diagnosed with advanced NSCLC, At baseline and for up to 5 years|Distribution of treatment patterns in adult patients diagnosed with advanced NSCLC, At baseline and for up to 5 years|Distribution of Incidence of All Adverse Events (AEs), Approximately 5 years|Distribution of Severity of All Adverse Events (AEs), Approximately 5 years|Distribution of Management of All Adverse Events (AEs), Approximately 5 years|European Quality of Life-5 Dimensions (EQ-5D), At baseline and for up to 5 years|Lung Cancer Symptom Scale (LCSS), At baseline and for up to 5 years
This study intends to describe the real-life effectiveness and safety of nivolumab in advanced NSCLC patients in Germany, as well as the patient profile, pattern of use and the quality of life.